Brokers Set Expectations for Personalis FY2029 Earnings

Personalis, Inc. (NASDAQ:PSNL) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Personalis in a research note issued on Monday, January 27th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of $0.35 per share for the year. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.37) per share.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The firm had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same quarter in the prior year, the business earned ($0.51) earnings per share.

Several other research analysts have also weighed in on the company. Lake Street Capital lifted their target price on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $7.25 price objective on shares of Personalis in a report on Wednesday, January 8th.

Personalis Stock Performance

PSNL opened at $5.44 on Tuesday. Personalis has a twelve month low of $1.12 and a twelve month high of $7.20. The firm has a market cap of $384.34 million, a PE ratio of -3.24 and a beta of 1.75. The firm’s fifty day moving average is $4.90 and its two-hundred day moving average is $4.75.

Institutional Trading of Personalis

A number of institutional investors have recently modified their holdings of PSNL. Jane Street Group LLC boosted its position in Personalis by 154.3% during the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after acquiring an additional 99,671 shares during the last quarter. ARK Investment Management LLC boosted its holdings in Personalis by 11.4% during the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after purchasing an additional 723,637 shares during the last quarter. Walleye Capital LLC bought a new position in Personalis in the third quarter valued at $897,000. Barclays PLC increased its stake in Personalis by 45.4% in the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock valued at $352,000 after buying an additional 20,444 shares during the last quarter. Finally, State Street Corp lifted its position in Personalis by 34.5% during the 3rd quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after buying an additional 44,900 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.